Login / Signup

Patient utilization survey of mirabegron prescribed for overactive bladder.

Päivi Rahkola-SoisaloMarcin BalcerzakJarno RuotsalainenTomi S Mikkola
Published in: Investigative and clinical urology (2019)
In this Finnish population, 50.7% of the participants continued using mirabegron after 6 months. The prescription site seemed to be important for persistent use, which may be related to patient counseling. Younger patients were more likely to benefit from treatment with mirabegron.
Keyphrases
  • end stage renal disease
  • case report
  • newly diagnosed
  • chronic kidney disease
  • peritoneal dialysis
  • prognostic factors
  • patient reported outcomes
  • hepatitis c virus
  • human immunodeficiency virus
  • antiretroviral therapy